Home Search

drug development - search results

If you're not happy with the results, please do another search

The Cancer Drug Development Forum

Open Access Government (May 2018) "Thanks for the information. We have already tweeted and shared the article with our contacts. Thanks for this opportunity and feel free to contact me should you have future editions on the topic of cancer."   Marjorie Recorbet, The Cancer Drug Development Forum – CDDF
early drug development

IDEAS: improving design, evaluation and analysis of early drug development studies

Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University explores a novel approach to Ph.D. training for those in the pharmaceutical industry
drug development for neurodegenerative diseases concept

Time for a change of tack on drug development for neurodegenerative diseases?

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

The evolution of malaria drug development

David H Peyton at Portland State University outlines how research has discovered that heme is key to malaria drug development

Drug development for neurodegenerative diseases

Professor Duncan McHale, Head Global Exploratory Development at UCB discusses the challenge of developing drugs to treat neurodegenerative diseases

The evolution of malaria drug development

David H Peyton at Portland State University outlines how research has discovered that heme is key to malaria drug development

The pursuit for new strategies in drug development

Prof. Dr. Tanja Gaich, of the University of Konstanz – Department of Chemistry discusses new strategies in drug development and the challenges involved
Paediatric oncology drug development conference 2016

Innovative oncology drug development: Why not children?

SIOPE asks why therapies made available for adults are not extended to children with cancer, and why paediatric oncology drug development is lagging behind Thanks to the increasing introduction of molecular targeting and personalised medicine strategies, innovative medicines and treatments are nowadays available for adults with cancer. Widespread access to...
drug development for neurodegenerative diseases concept

Time for a change of tack on drug development for neurodegenerative diseases?

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

Drug development for cancer and inflammatory disease

Sumith A Kularatne, Vice President of Research and Development at On Target Laboratories shares the research strides he has made in drug development
pills

Reclassifying neurodegenerative diseases for drug development

Professor Duncan McHale, Head Global Exploratory Development, UCB discusses reclassifying neurodegenerative diseases to enable drug development and to help patients... Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer.  By 2020 there will be more than 40 million individuals in the world with Alzheimer’s disease and...
drug

Drug development for Alzheimer’s disease

Ramón Cacabelos, of EuroEspes Biomedical Research Center discusses the strides being made in drug development for Alzheimer's disease... Alzheimer’s disease (AD) is a major problem of health and a national priority in developed countries. Despite enormous efforts by governments, the scientific community and the pharmaceutical industry over the past 50 years,...

Drug development for Alzheimer’s disease

Alzheimer's disease (AD) is a major problem of health and a national priority in developed countries. Despite enormous efforts by governments, the scientific community and the pharmaceutical industry over the past 50 years, no therapeutic breakthroughs have yet been achieved, and the drugs available for the treatment of AD...

The development of anti-infective drugs

University of Strathclyde’s Professor Colin J Suckling shares research being undertaken into anti-infective and immunomodulatory drug discovery programmes

Development of multiple drug resistance (MDR)

Terra G. Arnason and Troy A.A. Harkness from the Departments of Medicine, and Anatomy and Cell Biology at the University of Saskatchewan detail current strategies to prevent or reverse multiple drug resistant malignancy… Multiple drug resistance (MDR) can be present from the outset (inherent) or develop (acquired) in response to...
The role of chemistry in drug discovery and development

The role of chemistry in drug discovery and development

Sriram Radhakrishnan, Healthcare Analyst at Frost & Sullivan details the vital role chemistry plays in drug discovery and development Drug discovery and development is one of the most complex and expensive activities within the framework of the pharmaceutical industry. It encompasses a wide array of end-to-end activities with a plethora...
treat COVID-19, drug

Existing drugs should be used to treat COVID-19 instead of vaccine

Researchers say we should repurpose existing drugs, which would be faster than waiting for a "magic bullet" vaccine to treat COVID-19.
computer simulations, CECAM

The development of science: A focus on computer simulations

Ignacio Pagonabarraga, Director of CECAM, lifts the lid on the field of computer simulations and the crucial role they have played in the development of science since the second half of the last century.
early stages of COVID-19, ACE2

Researchers test drug that stops early stages of COVID-19

Dr. Josef Penninger led an international team from the University of British Columbia to pioneer a trial drug that could stop infection in the early stages of COVID-19.
academic drug discovery research

The ‘why’ and ‘what’ of academic drug discovery research at the University of Strathclyde

Prof Colin J Suckling OBE DSc FRSE from the Department of Pure & Applied Chemistry, details the ‘why’ and ‘what’ of academic drug discovery research at the University of Strathclyde, as well as his thoughts on the value of a chemistry degree.

Follow Open Access Government